Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | – | $6,229 | $7,004 | $4,976 |
| Short-Term Investments | – | $0 | $0 | $0 |
| Receivables | – | $74 | $2,780 | $642 |
| Inventory | – | $0 | $1,260 | $0 |
| Other Curr. Assets | – | $1,050 | $2,477 | $1,686 |
| Total Curr. Assets | – | $8,662 | $11,121 | $7,694 |
| Property Plant & Equip (Net) | – | $1,669 | $1,830 | $848 |
| Goodwill | – | $427 | $0 | $0 |
| Intangibles | – | $26 | $48 | $645 |
| Long-Term Investments | – | $1,946 | $2,804 | $2,782 |
| Tax Assets | – | $1 | -$2,462 | -$2,782 |
| Other NC Assets | – | $115 | $2,941 | $2,991 |
| Total NC Assets | – | $4,184 | $5,161 | $4,484 |
| Other Assets | – | $0 | $0 | $0 |
| Total Assets | – | $12,846 | $16,282 | $12,178 |
| Liabilities | – | – | – | – |
| Payables | – | $1,060 | $1,243 | $3,411 |
| Short-Term Debt | – | $0 | $0 | $0 |
| Tax Payable | – | $0 | $0 | $0 |
| Deferred Revenue | – | $0 | $509 | $763 |
| Other Curr. Liab. | – | $895 | $1,135 | $1,755 |
| Total Curr. Liab. | – | $2,416 | $2,932 | $6,092 |
| LT Debt | – | $0 | $0 | -$13 |
| Deferred Rev, NC | – | $0 | $0 | $4,486 |
| Deferred Tax Liab, NC | – | $0 | $0 | $13 |
| Other NC Liab. | – | $6,331 | $6,144 | $217 |
| Total NC Liab. | – | $7,165 | $7,046 | $5,067 |
| Other Liabilities | – | $0 | $0 | $0 |
| Cap. Leases | – | $989 | $1,058 | $536 |
| Total Liabilities | – | $9,581 | $9,978 | $11,159 |
| Equity | – | – | – | – |
| Pref Stock | – | $0 | $0 | $0 |
| Common Stock | – | $8,216 | $32,949 | $78,585 |
| Retained Earnings | – | -$361,417 | -$358,372 | -$353,687 |
| AOCI | – | $356,466 | $331,727 | $269,804 |
| Other Equity | – | $0 | $0 | $0 |
| Total Equity | – | $3,265 | $6,304 | $1,019 |
| Supplemental Information | – | – | – | – |
| Minority Interest | – | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | – | $12,846 | $16,282 | $12,178 |
| Net Debt | $0 | -$6,229 | -$7,004 | -$4,989 |